Prednisolone-Induced Cushing's syndrome: A case report
1 Department of Pharmaceutics, CMR College of Pharmacy, Hyderabad, Telangana, India.
2 Department of Pharm D, CMR College of Pharmacy, Hyderabad, Telangana, India.
3 Department of chemistry, CMR College of Pharmacy, Hyderabad, Telangana, India.
Review Article
World Journal of Advanced Research and Reviews, 2024, 21(01), 2471–2473
Article DOI: 10.30574/wjarr.2024.21.1.0056
Publication history:
Received on 28 November 2023; revised on 23 January 2024; accepted on 26 January 2024
Abstract:
Objective: Prednisolone, a frequently prescribed corticosteroid, is linked to diverse adverse effects, including Cushing's syndrome.
Material and Methods: This report details a case of prednisolone-induced Cushing's syndrome in a 6-year-old girl diagnosed with Acute Disseminated Encephalomyelitis (ADEM). Prednisolone was administered to manage inflammation associated with ADEM. Subsequent to the tapering of prednisolone, the patient exhibited progressive weight gain, facial rounding, fatigue, and muscle weakness. Clinical examination revealed classic manifestations of Cushing's syndrome, including central obesity, moon facies, and proximal muscle weakness. Laboratory analysis confirmed elevated serum cortisol levels and suppressed adrenocorticotropic hormone (ACTH), confirming exogenous Cushing's syndrome induced by prednisolone. The patient's prednisolone dosage was gradually reduced under careful medical supervision. Regular follow-ups were conducted to monitor symptoms, weight fluctuations, and hormonal levels. With the decrease in prednisolone dosage, the patient's symptoms showed gradual improvement.
Results and conclusion: Prednisolone-induced Cushing's syndrome arises as a recognized complication of corticosteroid therapy, primarily characterized by the suppression of the hypothalamic-pituitary-adrenal axis. Early awareness of this adverse effect is pivotal for prompt identification and management. This case emphasizes the significance of vigilant monitoring and judicious use of prednisolone to mitigate adverse effects like Cushing's syndrome. Swift recognition, dose adjustments, and a gradual tapering of corticosteroids play a crucial role in effectively managing this condition for optimal patient outcomes.
Keywords:
Prednisolone; Cushing’s syndrome; Acute Disseminated Encephalomyelitis
Full text article in PDF:
Copyright information:
Copyright © 2024 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0